Europe Has Its Own Biotech Star as Argenx Soars on Trial Success

Argenx’s Vyvgart late-stage study results are setting up the next regulatory steps, according to the update, with approval viewed as highly likely. The drug’s progress could also provide another growth lever if regulators clear it, reinforcing investor interest in the company’s pipeline momentum. The report also frames the timing as part of a broader biotech rally on both sides of the Atlantic, where sentiment has moved sharply in recent sessions. Moderna Inc. saw extreme share price swings during the week, highlighting how volatile biotech stocks can be as trial milestones draw nearer.